Why the study?
Does the measurement of circulating inflammatory markers (fibrinogen, CRP, Lp-PLA2, IL-6) improve coronary heart disease risk prediction?
Does the measurement of circulating inflammatory markers (fibrinogen, CRP, Lp-PLA2, IL-6) improve coronary heart disease risk prediction?
This review highlights the potential utility and outstanding uncertainties of using inflammatory markers like CRP and fibrinogen for cardiovascular risk prediction.
Does not support routine use of these markers for CHD risk prediction; leaves open their incremental value beyond standard factors.
Cardiovascular disease is the leading cause of global mortality, with coronary heart disease (CHD) its major manifestation. Although inflammation, the body's response to noxious stimuli, is implicated in several stages of CHD development, the relevance of circulating levels of markers of inflammation to CHD risk remains uncertain. This review summarizes available epidemiological evidence for four emerging inflammatory markers implicated in CHD (fibrinogen, C-reactive protein, lipoprotein-associated phospholipase A2 and interleukin-6); considers their likely utility in cardiovascular risk prediction; and outlines areas of outstanding uncertainty.
No takes yet. Share an insight, caveat, or question.
Sarwar et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: